Bayer wins a way out of Roundup lawsuits, but cancer claims remain contested

A Missouri judge approved a multibillion-dollar settlement covering tens of thousands of Roundup claims. Bayer sees a path to limiting litigation; plaintiffs’ lawyers say the deal offers relief as court options narrow.
Bayer wins a way out of Roundup lawsuits, but cancer claims remain contested

Bayer wins a way out of Roundup lawsuits, but cancer claims remain contested
A Missouri judge has approved Bayer’s multibillion-dollar settlement of Roundup cancer claims, offering the company a route to contain years of litigation while leaving the central dispute over glyphosate’s risks unresolved.

The settlement was reported as $7.25 billion by one account and about $7 billion by another. It is intended to resolve nearly all current and future U.S. claims, after Bayer faced roughly 65,000 lawsuits from people who said Roundup exposure caused cancer. Judge Timothy Boyer found the deal “fair, reasonable and adequate,” rejecting objections that individual payouts could be too low. He also warned that delaying payment could leave some claimants, including terminally ill people, waiting “an indeterminate number of years.”

Bayer cast approval as a business milestone, saying it would help mitigate the risks of pending and future litigation. The company has long maintained that glyphosate is safe and that studies do not show it causes cancer. The conservative account likewise emphasizes Bayer’s denial of wrongdoing, notes that the company has changed the formula of residential Roundup, and cites the EPA’s position that glyphosate is not cancer-causing when used as directed.

But the settlement lands amid a changing legal landscape. The U.S. Supreme Court recently ruled against a plaintiff in a case involving Roundup warnings, finding federal pesticide law barred the state-law failure-to-warn claim. Plaintiffs’ lawyer Christopher Seeger said that decision narrowed victims’ ability to pursue claims in court, while welcoming the settlement as a means of getting relief to them quickly.

The deal does not end every case: some federal lawsuits remain pending, and Bayer says about 200 are still being litigated. The approval therefore marks a major effort to cap exposure, not a resolution of the scientific and legal arguments over Roundup.

Write a comment